![Israel's Teva sees sharp rise in revenue next year boosted by new migraine drug - Business - Haaretz.com Israel's Teva sees sharp rise in revenue next year boosted by new migraine drug - Business - Haaretz.com](https://img.haarets.co.il/img/1.7194671/3872273389.jpg?precrop=1425,1424,x572,y24&width=1200&height=1200)
Israel's Teva sees sharp rise in revenue next year boosted by new migraine drug - Business - Haaretz.com
![Teva launches generic version of VESIcare (solifenacin succinate) tablets in US - Pharmaceutical Business review Teva launches generic version of VESIcare (solifenacin succinate) tablets in US - Pharmaceutical Business review](https://www.pharmaceutical-business-review.com/wp-content/uploads/2019/04/1280px-TevaCanada2.jpg)
Teva launches generic version of VESIcare (solifenacin succinate) tablets in US - Pharmaceutical Business review
![2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download 2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download](https://images.slideplayer.com/22/6352607/slides/slide_2.jpg)
2nd Annual NASDAQ TASE Israeli Investor Conference Dan Suesskind, CFO Teva Pharmaceutical Industries Ltd. November 27, ppt download
![Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire](https://mms.businesswire.com/media/20210505005037/en/739014/5/teva_RGB_JPEG.jpg)
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire
Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with
![Teva and Regeneron Announce Positive Results from Phase 3 Trial of Fasinumab in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip | Specialty Pharma Journal Teva and Regeneron Announce Positive Results from Phase 3 Trial of Fasinumab in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip | Specialty Pharma Journal](https://www.spjnews.com/wp-content/uploads/2015/04/Teva.jpg)
Teva and Regeneron Announce Positive Results from Phase 3 Trial of Fasinumab in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip | Specialty Pharma Journal
![حسن سجواني 🇦🇪 Hassan Sajwani on Twitter: "Teva Pharmaceuticals, an Israeli company, is shipping >6 million doses of #hydroxychloroquine sulfate tablets thru wholesalers to hospitals across U.S. to meet urgent demand for حسن سجواني 🇦🇪 Hassan Sajwani on Twitter: "Teva Pharmaceuticals, an Israeli company, is shipping >6 million doses of #hydroxychloroquine sulfate tablets thru wholesalers to hospitals across U.S. to meet urgent demand for](https://pbs.twimg.com/media/ETkFfpaXQAEtlc3.jpg:large)